MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Lepodisiran

  • Home
  • Lepodisiran
Lepodisiran’s Impact on Oxidized Phospholipids in Lipoprotein(a): Advancing Cardiovascular Risk Reduction
Posted inCardiology news

Lepodisiran’s Impact on Oxidized Phospholipids in Lipoprotein(a): Advancing Cardiovascular Risk Reduction

Posted by By MedXY 09/06/2026
Lepodisiran, an siRNA targeting Lp(a), significantly reduces oxidized phospholipids on apo(a) and apoB, highlighting its therapeutic potential in lowering cardiovascular risk linked to elevated Lp(a).
Read More
  • Clinical Utility of a 30% Reduction in VCTE-Derived Liver Stiffness Measurement for Identifying Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis
  • Reevaluating Colorectal Cancer Surveillance in Inflammatory Bowel Disease: The Role of Family History Beyond Early-Onset Cases
  • Ticagrelor-Aspirin Dual Therapy After Thrombolysis in Moderate Ischemic Stroke: Insights from Infarct Patterns in the TAPIS Trial
  • Cilostazol Therapy in Intracerebral Hemorrhage: Enhancing Dural Lymphatic Function for Neuroprotection
  • CSF Biomarkers as Indicators of Disease Severity in Probable Cerebral Amyloid Angiopathy: Insights Beyond MRI
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top